Aquestive Therapeutics AQST Stock
Aquestive Therapeutics Price Chart
Aquestive Therapeutics AQST Financial and Trading Overview
| Aquestive Therapeutics stock price | 4.66 USD |
| Previous Close | 4.5 USD |
| Open | 4.54 USD |
| Bid | 2.67 USD x 200 |
| Ask | 4.78 USD x 200 |
| Day's Range | 4.52 - 4.72 USD |
| 52 Week Range | 2.93 - 7.55 USD |
| Volume | 2.01M USD |
| Avg. Volume | 2.51M USD |
| Market Cap | 584.88M USD |
| Beta (5Y Monthly) | 1.428 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.66 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 9.33 USD |
AQST Valuation Measures
| Enterprise Value | 545.43M USD |
| Trailing P/E | N/A |
| Forward P/E | -8.175439 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 10.813768 |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | 10.084 |
| Enterprise Value/EBITDA | -10.449 |
Trading Information
Aquestive Therapeutics Stock Price History
| Beta (5Y Monthly) | 1.428 |
| 52-Week Change | 20.72% |
| S&P500 52-Week Change | 18.67% |
| 52 Week High | 7.55 USD |
| 52 Week Low | 2.93 USD |
| 50-Day Moving Average | 4.17 USD |
| 200-Day Moving Average | 4.49 USD |
AQST Share Statistics
| Avg. Volume (3 month) | 2.51M USD |
| Avg. Daily Volume (10-Days) | 5.29M USD |
| Shares Outstanding | 125.51M |
| Float | 114.68M |
| Short Ratio | 10.01 |
| % Held by Insiders | 2.84% |
| % Held by Institutions | 58.63% |
| Shares Short | 18.05M |
| Short % of Float | 15.06% |
| Short % of Shares Outstanding | 14.38% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | June 30, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | -144.63% |
| Operating Margin (ttm) | -59.50% |
| Gross Margin | 67.03% |
| EBITDA Margin | -96.51% |
Management Effectiveness
| Return on Assets (ttm) | -29.19% |
| Return on Equity (ttm) | N/A |
Income Statement
| Revenue (ttm) | 54.09M USD |
| Revenue Per Share (ttm) | 0.45 USD |
| Quarterly Revenue Growth (yoy) | 38.10% |
| Gross Profit (ttm) | 36.26M USD |
| EBITDA | -52201000 USD |
| Net Income Avi to Common (ttm) | -78227000 USD |
| Diluted EPS (ttm) | -0.66 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 98.49M USD |
| Total Cash Per Share (mrq) | 0.79 USD |
| Total Debt (mrq) | 59.03M USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 7.191 |
| Book Value Per Share (mrq) | -0.451 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -45365000 USD |
| Levered Free Cash Flow (ttm) | -26891876 USD |
Profile of Aquestive Therapeutics
| Country | United States |
| State | NJ |
| City | Warren |
| Address | 30 Technology Drive |
| ZIP | 07059 |
| Phone | 908 941 1900 |
| Website | https://www.aquestive.com |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector(s) | Healthcare |
| Full Time Employees | 147 |
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; EMYLIF, an oral film formulation of riluzole; ONDIF, an oral soluble film formulation of ondansetron; SYMPAZAN, an oral soluble film formulation of clobazam used for the treatment of seizures associated with a rare, intractable form of epilepsy; KYNMOBI, a sublingual film formulation of apomorphine; and AZSTARYS, an fda-approved, once-daily product for the treatment of ADHD in patients age 6 years or older. The company's proprietary pipeline products include Anaphylm, an epinephrine sublingual film, which is in phase 3 clinical trial for the emergency treatment of allergic reactions, including anaphylaxis; and AQST-108, a topical gel that is in phase 2 clinical trial for the treatment of alopecia areata. In addition, it develops PharmFilm technology for patients suffering from certain central nervous system disorders; and Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.
Q&A For Aquestive Therapeutics Stock
What is a current AQST stock price?
Aquestive Therapeutics AQST stock price today per share is 4.66 USD.
How to purchase Aquestive Therapeutics stock?
You can buy AQST shares on the Tech Market Middle exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Aquestive Therapeutics?
The stock symbol or ticker of Aquestive Therapeutics is AQST.
Which industry does the Aquestive Therapeutics company belong to?
The Aquestive Therapeutics industry is Drug Manufacturers - Specialty & Generic.
How many shares does Aquestive Therapeutics have in circulation?
The max supply of Aquestive Therapeutics shares is 125.51M.
What is Aquestive Therapeutics Price to Earnings Ratio (PE Ratio)?
Aquestive Therapeutics PE Ratio is now.
What was Aquestive Therapeutics earnings per share over the trailing 12 months (TTM)?
Aquestive Therapeutics EPS is -0.66 USD over the trailing 12 months.
Which sector does the Aquestive Therapeutics company belong to?
The Aquestive Therapeutics sector is Healthcare.
Aquestive Therapeutics AQST included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
26085.56 USD — |
-0.36
|
3.1B USD — | 25910.82 USD — | 26103.21 USD — | — - | 3.1B USD — |
|
Stlmt ID US Tech Biotechnology
NBX
US
|
3995.9 USD — |
-4.37
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
|
US Tech Global Market Composite
NQGM
US
|
2304.06 USD — |
-1.52
|
— — | 2285.97 USD — | 2317.25 USD — | — - | — — |
|
US Tech Biotechnology
NBI
US
|
7237.54 USD — |
-0.65
|
— — | 7170.25 USD — | 7244.82 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1360.99 USD — |
-0.5
|
— — | 1351.98 USD — | 1362.71 USD — | — - | — — |
- {{ link.label }} {{link}}
